164 related articles for article (PubMed ID: 9193208)
1. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis.
Nance PW; Sheremata WA; Lynch SG; Vollmer T; Hudson S; Francis GS; O'Connor P; Cohen JA; Schapiro RT; Whitham R; Mass MK; Lindsey JW; Shellenberger K
Arch Neurol; 1997 Jun; 54(6):731-6. PubMed ID: 9193208
[TBL] [Abstract][Full Text] [Related]
2. Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety.
Vakhapova V; Auriel E; Karni A
Clin Neuropharmacol; 2010 May; 33(3):151-4. PubMed ID: 20502134
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group.
Neurology; 1994 Nov; 44(11 Suppl 9):S70-8. PubMed ID: 7970014
[TBL] [Abstract][Full Text] [Related]
4. Prospective assessment of tizanidine for spasticity due to acquired brain injury.
Meythaler JM; Guin-Renfroe S; Johnson A; Brunner RM
Arch Phys Med Rehabil; 2001 Sep; 82(9):1155-63. PubMed ID: 11552184
[TBL] [Abstract][Full Text] [Related]
5. A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients.
Henney HR; Runyan JD
Int J Clin Pract; 2008 Feb; 62(2):314-24. PubMed ID: 18199279
[TBL] [Abstract][Full Text] [Related]
6. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group.
Smith C; Birnbaum G; Carter JL; Greenstein J; Lublin FD
Neurology; 1994 Nov; 44(11 Suppl 9):S34-42; discussion S42-3. PubMed ID: 7970009
[TBL] [Abstract][Full Text] [Related]
7. Treatment of spasticity with tizanidine in multiple sclerosis.
Lapierre Y; Bouchard S; Tansey C; Gendron D; Barkas WJ; Francis GS
Can J Neurol Sci; 1987 Aug; 14(3 Suppl):513-7. PubMed ID: 3676923
[TBL] [Abstract][Full Text] [Related]
8. Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke.
Gelber DA; Good DC; Dromerick A; Sergay S; Richardson M
Stroke; 2001 Aug; 32(8):1841-6. PubMed ID: 11486114
[TBL] [Abstract][Full Text] [Related]
9. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders.
Wagstaff AJ; Bryson HM
Drugs; 1997 Mar; 53(3):435-52. PubMed ID: 9074844
[TBL] [Abstract][Full Text] [Related]
10. Tizanidine--initial pharmacokinetic studies in patients with spasticity.
Heazlewood V; Symoniw P; Maruff P; Eadie MJ
Eur J Clin Pharmacol; 1983; 25(1):65-7. PubMed ID: 6617726
[TBL] [Abstract][Full Text] [Related]
11. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam.
Groves L; Shellenberger MK; Davis CS
Adv Ther; 1998; 15(4):241-51. PubMed ID: 10186943
[TBL] [Abstract][Full Text] [Related]
12. Update on tizanidine for muscle spasticity and emerging indications.
Malanga G; Reiter RD; Garay E
Expert Opin Pharmacother; 2008 Aug; 9(12):2209-15. PubMed ID: 18671474
[TBL] [Abstract][Full Text] [Related]
13. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis.
Eyssette M; Rohmer F; Serratrice G; Warter JM; Boisson D
Curr Med Res Opin; 1988; 10(10):699-708. PubMed ID: 3286128
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group.
Nance PW; Bugaresti J; Shellenberger K; Sheremata W; Martinez-Arizala A
Neurology; 1994 Nov; 44(11 Suppl 9):S44-51; discussion S51-2. PubMed ID: 7970010
[TBL] [Abstract][Full Text] [Related]
15. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury.
Kamen L; Henney HR; Runyan JD
Curr Med Res Opin; 2008 Feb; 24(2):425-39. PubMed ID: 18167175
[TBL] [Abstract][Full Text] [Related]
16. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
Smolenski C; Muff S; Smolenski-Kautz S
Curr Med Res Opin; 1981; 7(6):374-83. PubMed ID: 7016449
[TBL] [Abstract][Full Text] [Related]
17. [The usefulness of tizanidine. A one-year follow-up of the treatment of spasticity in infantile cerebral palsy].
Vásquez-Briceño A; Arellano-Saldaña ME; León-Hernández SR; Morales-Osorio MG
Rev Neurol; 2006 Aug 1-15; 43(3):132-6. PubMed ID: 16871477
[TBL] [Abstract][Full Text] [Related]
18. The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen.
Stien R; Nordal HJ; Oftedal SI; Slettebø M
Acta Neurol Scand; 1987 Mar; 75(3):190-4. PubMed ID: 3554879
[TBL] [Abstract][Full Text] [Related]
19. Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud).
Emre M; Leslie GC; Muir C; Part NJ; Pokorny R; Roberts RC
J Neurol Neurosurg Psychiatry; 1994 Nov; 57(11):1355-9. PubMed ID: 7964811
[TBL] [Abstract][Full Text] [Related]
20. An approach to switching patients from baclofen to tizanidine.
Brenner R; Hyman N; Knobler R; O'Brien M; Stephan T
Hosp Med; 1998 Oct; 59(10):778-82. PubMed ID: 9850294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
